GlassScriptPhysician profile
Kelli L Culpepper
NPI 1376615203
$5,041.37
in general payments reported to CMS, 2019-2025
42 companies · $464 in 2025
The $464 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,137 · 2020: $375 · 2021: $364 · 2022: $492 · 2023: $772 · 2024: $438 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $1,735.07 | 2019-2024 | |
| Abbvie INC. | $542.89 | 2019-2023 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $382.48 | 2023-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $280.41 | 2019-2025 | Slynd |
| Mayne Pharma Commercial LLC | $268.52 | 2022-2025 | |
| Pfizer INC. | $260.02 | 2019-2024 | |
| Organon LLC | $176.20 | 2022-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $174.22 | 2023-2025 | Myfembree |
| Hologic Sales and Service, LLC | $115.91 | 2019-2025 | Thinprep 2000 Processor, Aptima, Affirm Prone Biopsy System |
| Mylan Pharmaceuticals INC. | $111.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $69.82 | 2019-2021 | |
| Sage Therapeutics, LLC | $64.52 | 2024-2025 | Zurzuvae |
| Monaghan Medical Corporation | $56.14 | 2024 | Aerobika |
| Myovant Sciences INC. | $49.87 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $48.56 | 2024-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $44.28 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $44.17 | 2019-2020 | |
| Northgate Technologies, INC. | $41.03 | 2024 | Stimsite |
| Ethicon US, LLC | $40.72 | 2025 | Enseal |
| Allergan, INC. | $40.55 | 2019 | |
| Intuitive Surgical, INC. | $40.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.74 | 2020-2022 | |
| Aspira Women'S Health INC | $34.78 | 2019-2022 | |
| Shield Therapeutics INC | $34.72 | 2023-2025 | Accrufer |
| Pacira Pharmaceuticals Incorporated | $30.51 | 2021-2022 | |
| Gynesonics, INC. | $29.40 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Lupin INC. | $27.23 | 2020 | |
| Innovation Technologies INC | $24.11 | 2023 | Irrisept |
| Medtronic, INC. | $23.34 | 2023 | V-Loc 180 |
| Integra Lifesciences Corporation | $22.95 | 2025 | Duraseal Exact Spinal Sealant System, Cusa Clarity, Codman Hakim |
| Becton, Dickinson and Company | $21.34 | 2019 | |
| Smith+Nephew, INC. | $19.66 | 2019 | |
| Duchesnay USA Incorporated | $19.18 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.86 | 2025 | Qelbree |
| Agile Therapeutics, INC. | $17.50 | 2021 | |
| Novum Pharma, LLC | $16.36 | 2019 | |
| Boston Scientific Corporation | $16.10 | 2025 | General - Female Sui |
| Molnlycke Health Care US, LLC | $15.02 | 2023 | Mepilex Border, Mepilex Border Post-Op Ag, Avance |
| Alnylam Pharmaceuticals INC. | $14.40 | 2021 | |
| Therapeuticsmd, INC. | $11.71 | 2020 | |
| Evofem Biosciences, INC. | $11.66 | 2021 | |
| Channel Medsystems, INC. | $10.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Culpepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.